Journal: Cancer discovery
This publication reports that, in patients with mismatch repair–deficient (dMMR) or microsatellite instability–high (MSI-H) metastatic colorectal cancer, adding chemotherapy and bevacizumab to atezolizumab substantially improved progression-free survival compared with atezolizumab alone.
- Finding: The combination of chemotherapy, bevacizumab, and atezolizumab led to significantly longer progression-free survival than atezolizumab monotherapy.
- Rationale: dMMR/MSI-H patients often eventually progress on immune checkpoint inhibitor monotherapy.
- Implication: A triplet strategy—chemotherapy plus anti–VEGF (bevacizumab) plus PD-L1 blockade (atezolizumab)—may provide more durable disease control than immunotherapy alone.
- Clinical relevance: This regimen could represent a more effective therapeutic approach for this high-risk group.